Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Äîêàçàòåëüíàÿ ìåäèöèíà

Äîêàçàòåëüíàÿ ìåäèöèíà Ðàçäåë ïðåäíàçíà÷åí äëÿ ïðîôåññèîíàëüíîãî îáùåíèÿ âðà÷åé è ñòóäåíòîâ-ìåäèêîâ ïî âîïðîñàì ìåòîäîëîãèè ÅÂÌ. Êîíñóëüòèðîâàíèå ïàöèåíòîâ â ýòîì ðàçäåëå íå ïðîâîäèòñÿ.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 29.11.2015, 01:25
Àâàòàð äëÿ GigaBaita
GigaBaita GigaBaita âíå ôîðóìà Ïîë æåíñêèé
çàáàíåí
 
Ðåãèñòðàöèÿ: 29.11.2015
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3
GigaBaita *
À ìíå êàæåòñÿ, ÷òî ïðîñòî êàæäîìó ñâîé ñïèñîê ïîäõîäèò
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 29.11.2015, 12:40
Àâàòàð äëÿ FilippovaYulia
FilippovaYulia FilippovaYulia âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 30.01.2011
Ãîðîä: Âîëãîãðàä
Ñîîáùåíèé: 15,438
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 6,376 ðàç(à) çà 6,132 ñîîáùåíèé
FilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåFilippovaYulia ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âû îøèáàåòåñü.
__________________
×òîáû ïîñòàâèòü äèàãíîç íåïðàâèëüíî, íàäî èìåòü îñîáûé òàëàíò è ïðåìíîãî ïîñòàðàòüñÿ: ñäåëàòü ÌÐÒ è ÊÒ âñåõ ëþáîïûòíûõ ìåñò áîëüíîãî, ðåíòãåíîâñêèå ñíèìêè îò ãîëîâû äî ïÿò, àíàëèçû âñåõ áèîæèäêîñòåé, ïðèãëàñèòü ïÿòîê-äðóãîé êîíñóëüòàíòîâ… Ñàì ÷åðò ïîòîì âî âñåì ýòîì íå ðàçáåðåòñÿ! Ï. Ðóäè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 30.11.2015, 14:18
Àâàòàð äëÿ SergeyPlyasunov
SergeyPlyasunov SergeyPlyasunov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 13.01.2002
Ãîðîä: Ñàìàðà, ÐÔ
Ñîîáùåíèé: 1,733
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 159 ðàç(à) çà 154 ñîîáùåíèé
SergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êàæäûé âûáèðàåò äëÿ ñåáÿ
æåíùèíó, ðåëèãèþ, äîðîãó.
(Þðèé Ëåâèòàíñêèé)

Îò ñåáÿ äîáàâëþ: Íåâåæäàì - åñòåñòâåííûé îòáîð!
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 18.12.2015, 13:46
dmitry_n dmitry_n âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 23.06.2013
Ãîðîä: Í
Ñîîáùåíèé: 47
Ñêàçàë(à) ñïàñèáî: 5
dmitry_n ýòîò ó÷àñòíèê ïîëîæèòåëüíî õàðàêòåðèçóåòñÿ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò FilippovaYulia Ïîñìîòðåòü ñîîáùåíèå
Âû îøèáàåòåñü.
Ïðîøó ïðîùåíèÿ, à åñëè äåéñòâèòåëüíî ïîäõîäèò? Äà, ïóñòü ïëàöåáî. Íó è ÷òî? Òà æå ïñèõîòåðàïèÿ, êîòîðóþ, ê ñîæàëåíèþ, çäåñü ëþáÿò íàçíà÷àòü ïðè âñåõ íåïîíÿòíûõ áîëåçíÿõ - òîæå ïëàöåáî. È íè÷åãî, íèêòî ïî÷åìó-òî íå êðèòèêóåò. À åñëè ðàñêðèòèêîâàííûé âäîëü è ïîïåð¸ê ïèðàöåòàì êîãî-òî ñòàâèò íà íîãè, òî, ìîæåò, ïëåâàòü íà ôîðìàëüíîñòè ÷òî "íå äîêàçàíî"?

Êîììåíòàðèè ê ñîîáùåíèþ:
SergeyPlyasunov îäîáðèë(à): Òîãäà âûáèðàéòå äåéñòâèòåëüíî ïóñòûøêè, ò.å. áåç âñÿêèõ ïîáî÷íûõ äåéñòâèé
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 28.12.2015, 22:39
AlexisZuboff AlexisZuboff âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2015
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3
AlexisZuboff *
Öèòàòà:
Ñîîáùåíèå îò SergeyPlyasunov Ïîñìîòðåòü ñîîáùåíèå
Âîò íàø¸ë áîëüøîé òåêñò - 267 ïðåïàðàòîâ!

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Î÷åíü ñòðàííî, ÷òî â ýòîò ñïèñîê ïîïàëè Êåïïðà è Äåïàêèí Õðîíî (íîìåð 117). Âàëüïðîåâàÿ êèñëîòà(Äåïàêèí, Êîíâóëåêñ, Êóíâóëüñîôèí) - ýòî óíèâåðñàëüíîå ïðîòèâîýïèëåïòè÷åñêîå ñðåäñòâî, ýôôåêòèâíî èñïîëüçóþùååñÿ ïðè ýïèëåïñèè ñ 60-õ ãîäîâ XX âåêà. Î äîêàçàòåëüíîé áàçå äàæå ñìåøíî ãîâîðèòü... Òûñÿ÷è èññëåäîâàíèé è òîííû ëèòåðàòóðû.  ïñèõèàòðèè âàëüïðîåâàÿ êèñëîòà îáîñíîâàííî ïðèìåíÿåòñÿ â êà÷åñòâå íîðìîòèìè÷åñêîãî ñðåäñòâà ïðè ðàññòðîéñòâàõ àôôåêòà. ×òî æå êàñàåòñÿ ïðåïàðàòà Êåïïðà(ëåâåòèðàöåòàì), òî ýòî îäíî èç ñðàâíèòåëüíî íîâûõ ïðîòèâîýïèëåïòè÷åñêèõ ñðåäñòâ, çàðåãèñòðèðîâàííîå â ÑØÀ â 1999 ãîäó (ó íàñ - â 2003 ãîäó) è îáëàäàþùåå íå òîëüêî õîðîøåé ïåðåíîñèìîñòüþ, íî è è ðÿäîì âàæíåéøèõ ïðåèìóùåñòâ, çíà÷èòåëüíî ðàñøèðÿþùèõ åãî êëèíè÷åñêîå ïðèìåíåíèå ïðè ýïèëåïñèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 29.12.2015, 16:49
Àâàòàð äëÿ SergeyPlyasunov
SergeyPlyasunov SergeyPlyasunov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 13.01.2002
Ãîðîä: Ñàìàðà, ÐÔ
Ñîîáùåíèé: 1,733
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 159 ðàç(à) çà 154 ñîîáùåíèé
SergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò AlexisZuboff Ïîñìîòðåòü ñîîáùåíèå
Î÷åíü ñòðàííî, ÷òî â ýòîò ñïèñîê ïîïàëè Êåïïðà è Äåïàêèí Õðîíî (íîìåð 117). ... Î äîêàçàòåëüíîé áàçå äàæå ñìåøíî ãîâîðèòü... Òûñÿ÷è èññëåäîâàíèé è òîííû ëèòåðàòóðû. ....
Óâàæàåìûé AlexisZuboff!
Çà÷åì òàê ìíîãî âîçìóùåíèé? Ïðîñòî, ïîæàëóéñòà, äàéòå ññûëêè íà ïîñëåäíèå ãàéäû è èñïûòàíèÿ ñ ýòèìè ïðåïàðàòàìè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 02.01.2016, 16:59
konst77 konst77 âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 26.06.2011
Ãîðîä: Êðàñíîÿðñê
Ñîîáùåíèé: 20
Ñêàçàë(à) ñïàñèáî: 18
konst77 *
Åùå îäèí ïîäîáíûé ñïèñîê [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 09.01.2016, 16:45
AlexisZuboff AlexisZuboff âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2015
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3
AlexisZuboff *
Öèòàòà:
Ñîîáùåíèå îò SergeyPlyasunov Ïîñìîòðåòü ñîîáùåíèå
Óâàæàåìûé AlexisZuboff!
Çà÷åì òàê ìíîãî âîçìóùåíèé? Ïðîñòî, ïîæàëóéñòà, äàéòå ññûëêè íà ïîñëåäíèå ãàéäû è èñïûòàíèÿ ñ ýòèìè ïðåïàðàòàìè.
Äîêàçàòåëüíûå èññëåäîâàíèÿ ýôôåêòèâíîñòè ëåâåòèðàöåòàìà ïðè ýïèëåïñèè:

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Levetiracetam*for partial seizures: results of a double-blind, randomized clinical trial).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Multicenter double-blind, randomized, placebo-controlled trial of*levetiracetam*as add-on therapy in patients with refractory partial seizures. European*Levetiracetam*Study Group)

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Efficacy and tolerability of*levetiracetam*3000 mg/d in patients with refractory partial seizures: a*multicenter,double-blind, responder-selected study evaluating monotherapy. European*Levetiracetam*Study Group).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Efficacy and safety of*levetiracetam*(up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: amulticenter,*randomized,*double-blind,*placebo-controlled*study).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Once-daily extended-release*levetiracetam*as adjunctive treatment of partial-onset seizures in patients with epilepsy: a*double-blind,*randomized,*placebo-controlled*trial).

Èññëåäîâàíèÿ ïî ýôôåêòèâíîñòè ëåâåòèðàöåòàìà â ïåäèàòðè÷åñêîé ïðàêòèêå:

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Double-blind*placebo-controlled*trial*of adjunctive*levetiracetam*in pediatric partial seizures).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Adjunctive*levetiracetam*in infants and young children with refractory partial-onset seizures).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Levetiracetam*as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two*randomized,*double-blind,*placebo-controlled*studies).

Èññëåäîâàíèå ïî íàëè÷èþ ïîëîæèòåëüíîãî íåéðîêîãíèòèâíîãî ýôôåêòà ó ëåâåòèðàöåòàìà:

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Neurocognitive effects of adjunctive*levetiracetam*in children with partial-onset seizures: a*randomized,*double-blind,*placebo-controlled, noninferiority*trial).

Åñòåñòâåííî, ÿ ïðèâ¸ë äàëåêî íå âñå èññëåäîâàíèÿ, äîêàçûâàþùèå ýôôåêòèâíîñòü ëåâåòèðàöåòàìà ïðè ýïèëåïñèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 09.01.2016, 17:23
AlexisZuboff AlexisZuboff âíå ôîðóìà Ïîë ìóæñêîé
Ñåðôåð
 
Ðåãèñòðàöèÿ: 28.12.2015
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 3
AlexisZuboff *
Öèòàòà:
Ñîîáùåíèå îò SergeyPlyasunov Ïîñìîòðåòü ñîîáùåíèå
Óâàæàåìûé AlexisZuboff!
Çà÷åì òàê ìíîãî âîçìóùåíèé? Ïðîñòî, ïîæàëóéñòà, äàéòå ññûëêè íà ïîñëåäíèå ãàéäû è èñïûòàíèÿ ñ ýòèìè ïðåïàðàòàìè.
Òåïåðü î Äåïàêèíå. Ìîÿ ðåàêöèÿ ñîâåðøåííî óìåñòíà. Èçâèíèòå, óâàæàåìûé êîëëåãà, íî ïðèâîäèòü äîêàçàòåëüñòâà î ýôôåêòèâíîñòè âàëüïðîåâîé êèñëîòû ïðè ýïèëåïñèè â 21 âåêå (!) — ýòî âñ¸ ðàâíî ÷òî ñ ïîëíîé ñåðü¸çíîñòüþ äîêàçûâàòü àíòèïñèõîòè÷åñêèé ýôôåêò ãàëîïåðèäîëà èëè ïðîòèâîâîñïàëèòåëüíûé ýôôåêò ó èáóïðîôåíà. Äàííûå ïðåïàðàòû ýôôåêòèâíî èñïîëüçóþòñÿ åù¸ ñ 60-õ ãîäîâ 20 âåêà.

Ýôôåêòèâíîñòü íîâûõ àíòèýïèëåïòè÷åñêèõ ïðåïàðàòîâ äîêàçûâàþò ïðèñîåäèíåíèåì èõ ê áàçîé òåðàïèè âàëüïðîàòàìè (1+ âàëüïðîàò), ïðèñîåäèíåíèåì ê äâóì (èëè òðåì) ïðåïàðàòàì ïðè ðåçèñòåíòíûõ
ôîðìàõ ýïèëåïñèè (1+1+âàëüïðîàò), ñðàâíèâàÿ èõ ñ ýôôåêòèâíîñòüþ ïðèñîåäèíÿåìîãî ê áàçîâîé òåðàïèè ïëàöåáî â êîíòðîëüíûõ ãðóïïàõ.
Íà "ÏàáÌåä'å" ìíîæåñòâî ïîäîáíûõ èññëåäîâàíèé.

À âîò íåêîòîðûå èññëåäîâàíèÿ ïî íàëè÷èþ íîðìîòèìè÷åñêîãî ýôôåêòà ó âàëüïðîàòà:

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Valproate*as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective,randomized,*double-blind,*placebo-controlled,*multicenter*study. European*Valproate*Mania Study Group).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder).
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 15.01.2016, 01:22
Àâàòàð äëÿ SergeyPlyasunov
SergeyPlyasunov SergeyPlyasunov âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 13.01.2002
Ãîðîä: Ñàìàðà, ÐÔ
Ñîîáùåíèé: 1,733
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 159 ðàç(à) çà 154 ñîîáùåíèé
SergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergeyPlyasunov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé AlexisZuboff!
Ñïàñèáî.
ß âû÷åðêíó ó ñåáÿ èç ñïèñêà ýòè ïðåïàðàòû è ñîîáùó ññûëêó íà Âàøè ññûëêè, íà ñàéò ñ êîòîðîãî ýòîò ñïèñîê âçÿë.
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 15.01.2016, 01:37
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò AlexisZuboff Ïîñìîòðåòü ñîîáùåíèå
Èññëåäîâàíèå ïî íàëè÷èþ ïîëîæèòåëüíîãî íåéðîêîãíèòèâíîãî ýôôåêòà ó ëåâåòèðàöåòàìà
Óòî÷íèë áû òîëüêî "Èññëåäîâàíèå ïî îòñóòñòâèþ ïîëîæèòåëüíîãî íåéðîêîãíèòèâíîãî ýôôåêòà ó ëåâåòèðàöåòàìà ïî ñðàâíåíèþ ñ ïëàöåáî":

...adjunctive levetiracetam on memory and attention as measured by validated and well-standardized neurocognitive instruments were no different from placebo in children aged 4–16 years with inadequately controlled partial-onset seizures.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 14.03.2016, 22:27
EMG EMG âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 08.02.2015
Ãîðîä: X
Ñîîáùåíèé: 2,634
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 982 ðàç(à) çà 937 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 2
EMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåEMG ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè! Âàæíî Âàøå ìíåíèå ïî ðåçóëüòàòàì ýòîãî èññëåäîâàíèÿ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 14.03.2016, 22:35
Àâàòàð äëÿ Karakush
Karakush Karakush âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 15.09.2009
Ãîðîä: Ãäå-òî â Ãåðìàíèè
Ñîîáùåíèé: 1,417
Ñêàçàë(à) ñïàñèáî: 6
Ïîáëàãîäàðèëè 442 ðàç(à) çà 404 ñîîáùåíèé
Karakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKarakush ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò EMG Ïîñìîòðåòü ñîîáùåíèå
Óâàæàåìûå êîëëåãè! Âàæíî Âàøå ìíåíèå ïî ðåçóëüòàòàì ýòîãî èññëåäîâàíèÿ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ìîæåò, ïðè÷èíà â ýòîì?

Öèòàòà:
Because this study was exploratory and had a relatively small sample size, the results should be confirmed in a large-scale, randomized clinical trial.
Âåäü [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
AUTHORS' CONCLUSIONS:
There is not enough evidence to evaluate the effect of cerebrolysin on survival and dependency in people with acute ischaemic stroke. High-quality and large-scale randomised controlled trials may help to gain a better understanding of the potential value of cerebrolysin in acute ischaemic stroke.

Êîììåíòàðèè ê ñîîáùåíèþ:
EMG îäîáðèë(à): Ñïàñèáî. Ñîëèäàðíà.
Iluhin îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 14.03.2016, 22:51
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êàê ïîíèìàþ, ýòî èññëåäîâàíèå ôàçû 2:

"This study was planned as an exploratory phase II trial. This design limits the degree of evidence obtained; thus, the results should be confirmed in a large-scale phase III trial."

êàê áû ïîäòâåðæäàþùåå íà ïðåäâàðèòåëüíîé ñòàäèè òå äàííûå, êîòîðûå áûëè ïîëó÷åíû ðàíåå ïðè àíàëèçå ïîäãðóïï [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

åùå ìîìåíòû - âëèòî áûëî ñâûøå ïîëëèòðû ãèäðîëèçàòà â òå÷åíèå òðåõ íåäåëü (òî åñòü åñëè ââîäèòü ïî 5-10 ìë 10-15 äíåé â çàâèñèìîñòè îò ôèí. âîçìîæíîñòåé ïàöèåíòà, òî íå ôàêò, ÷òî ýôôåêò áóäåò èäåíòè÷åí) ïëþñ ðåàáèëèòàöèîííàÿ ïðîãðàììà (áóäåò ëè ñåé ýôôåêò, åñëè ðåàáèëèòàöèþ íå ïðîâîäèòü â äîëæíîì îáüåìå - íåèçâåñòíî).

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
EMG îäîáðèë(à): Ñïàñèáî!
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 14.03.2016, 23:15
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,383
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ýêñïåðèìåíòû íà ãðûçóíàõ êàê ðàç è ïîêàçûâàþò äîçîçàâèñèìûé ýôôåêò, êîòîðûé íà÷èíàåòñÿ ñ 2.5 ìë/êã, ÷òî â ðàç 5-6 íèæå, íåæåëè ïðèìåíåííûå âûøå äîçû (30 ìë íà 60-80 êã âçðîñëîãî):
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 05:12.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.